State Street SPDR S&P Biotech ETF: (XBI)

(Real Time Quote from BATS) As of Oct 12, 2026 10:48 AM ET

$152.23 USD

-1.54 (-1.00%)

Volume: 1,097,281

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank	Definition
1	Strong Buy
2	Buy
3	Hold
4	Sell
5	Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

3 - Hold 3

Zacks News

Ride Out the Coronavirus Mayhem With These ETF Areas

by Sweta Jaiswal, FRM Published on April 23,2020

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.

6 Top-Ranked ETFs Beating the Market

by Sweta Killa Published on April 23,2020

With the start of the second quarter, the U.S. stock markets have regained momentum on easing coronavirus pandemic as well as unprecedented fiscal and monetary stimulus.

Biotech ETFs Gaining on Progress in Coronavirus Treatment

by Sweta Jaiswal, FRM Published on April 21,2020

The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.

ETFs to Rise as Gilead Drug Shows Promise in Coronavirus Cure

by Sweta Jaiswal, FRM Published on April 14,2020

Gilead Sciences (GILD) has ignited a ray of hope with its recently-released positive data on the role of remdesivir as a COVID-19 treatment.

Coronavirus Testing, Vaccines & Treatments: What You Should Know

by Neena Mishra Published on April 09,2020

We discuss latest developments in tests, vaccines and therapies for COVID-19.

Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development

by Sweta Jaiswal, FRM Published on April 01,2020

The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.